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Objective: Developmental disorders including cognitive deficit, hyperkinetic disorder,
and autistic behaviors are frequently comorbid in epileptic patients with SCN1Amuta-
tions. However, themechanisms underlying these developmental disorders are poorly
understood and treatments are currently unavailable. Using a rodent model with an
Scn1amutation, we aimed to elucidate the pathophysiologic basis and potential thera-
peutic treatments for developmental disorders stemming from Scn1amutations.
Methods: We conducted behavioral analyses on rats with the N1417H-Scn1a muta-
tion. With high-performance liquid chromatography, we measured dopamine and its
metabolites in the frontal cortex, striatum, nucleus accumbens, andmidbrain. Methyl-
phenidate was administered intraperitoneally to examine its effects on developmental
disorder–like behaviors and hyperthermia-induced seizures.
Results: Behavioral studies revealed that Scn1a-mutant rats had repetitive behavior,
hyperactivity, anxiety-like behavior, spatial learning impairments, and motor imbal-
ance. Dopamine levels in the striatum and nucleus accumbens in Scn1a-mutant rats
were significantly lower than those in wild-type rats. In Scn1a-mutant rats, methylphe-
nidate, by increasing dopamine levels in the synaptic cleft, improved hyperactivity,
anxiety-like behavior, and spatial learning impairments. Surprisingly, methylphenidate
also strongly suppressed hyperthermia-induced seizures.
Significance: Dysfunction of the mesolimbic dopamine reward pathway may contrib-
ute to the hyperactivity and learning impairments in Scn1a-mutant rats. Methylpheni-
date was effective for treating hyperactivity, learning impairments, and hyperthermia-
induced seizures. We propose that methylphenidate treatment may ameliorate not
only developmental disorders but also epileptic seizures in patients with SCN1Amuta-
tions.
KEY WORDS: Methylphenidate, Dopamine, Mesolimbic reward pathway, Scn1a,
Developmental disorders.
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The voltage-gated sodium channel a1 subunit, Nav1.1,
encoded by SCN1A, is mainly expressed in c-aminobutyric
acid (GABA)ergic interneurons and plays a crucial role in
the initiation and propagation of action potentials.1,2 Muta-
tions of SCN1A usually result in haploinsufficiency of
Nav1.1 and contribute to intractable epileptic syndromes.
SCN1A mutations are detected in 70–80% of patients with
Dravet syndrome3–5 and in 3–10% of patients with genetic
epilepsy with febrile seizures plus (GEFS+).6–8 In addition
to intractable epilepsy, patients with Dravet syndrome also
experience developmental disorders such as attention-defi-
cit/hyperactive disorder (ADHD), severe cognitive deficit,
autistic behaviors, and motor imbalance.9–12 GEFS+
patients with SCN1A mutations also exhibit psychiatric dis-
orders including anxiety disorder and Asperger syndrome.13
However, developmental disorders are not common in
GEFS+ patients, and simple febrile seizures is a phenotype
that be caused only by an SCN1A mutation.14 Most studies
of Dravet syndrome and GEFS+ focus on treating epileptic
symptoms, whereas comparatively fewer studies focus on
comorbid developmental disorders. As such, a treatment for
developmental disorders in these patients is not yet estab-
lished. Because these developmental disorders profoundly
disrupt patients’ quality of life, it is important to clarify the
pathophysiologic basis of and find an effective treatment for
these symptoms.
Animal models are useful tools to elucidate the mecha-
nisms of developmental disorders caused by single gene
mutations. We previously generated a GEFS+ rat model
with a N1417H-Scn1amutation and characterized its physi-
ologic properties.15 Using this rat model, the efficacy of
many anticonvulsant drugs on hyperthermia-induced sei-
zures (HIS) was comparable to that in patients with GEFS+
and Dravet syndrome.16
In this study, using Scn1a-mutant rats, we investigated
the pathophysiologic basis of developmental disorders and
potential therapeutics for Scn1a mutation. We found that
even without recurring seizures, Scn1a mutation leads to
neurodevelopmental behavioral disorders. Dopamine (DA)
levels in the striatum and nucleus accumbens (NA) in
Scn1a mutant rats were significantly lower than in wild-
type (WT) controls. Methylphenidate (MPH) treatment
improved hyperactivity and impaired spatial learning. In




We used male F344/NSlc-Scn1aKyo811 rats with a homo-
zygous N1417H missense mutation (Scn1a mutant rats;
National BioResource Project for Rat in Japan, Kyoto Uni-
versity, Japan)15 and WT littermate male rats. N1417H-
Scn1a mutation does not represent SCN1A mutations found
in human patients, which arise from random mutagenesis.
Animals were maintained under standard laboratory condi-
tion with a 12 h light/dark cycle with food and water avail-
able ad libitum. A general health and neurologic screen
was conducted before behavioral studies. WT and Scn1a
homozygous mutant rats were first observed in their home
cages for general health, and sensory and motor reflexes
were evaluated. Body weight at 5 weeks of age was mea-
sured.
All animal experiments were performed in accordance
with protocols approved by the Institutional Animal Care
and Use Committee of Okayama University.
Behavioral studies
Male rats at 5- to 8-weeks-old were used for all behav-
ioral analyses. All experiments were conducted in dedicated
behavioral testing rooms during the standard light phase,
usually between 13:00 and 17:00 h. Rats were brought to a
holding room in the hallway of the testing area at least 1 h
prior to the start of the behavioral test. Testing order was as
follows: observation of repetitive self-grooming behavior,
open field test, elevated plus-maze test, three-chamber
social interaction test, Barnes maze test, and rotarod test.
All behavioral tests were performed in the same order and
with 1–2 day intervals. All experiments were done blind to
genotype and treatment. Detailed procedures were
described in Data S1.
Video-EEGmonitoring
To confirm whether spontaneous seizures occurred, we
recorded video-EEG as previously described.16 Briefly, at
4 weeks of age, rats were implanted with stainless steel
screw electrodes bilaterally into the frontal (anteroposterior
[AP]: +0.5 mm; mediolateral [ML]: 3.0 mm from
bregma) and occipital cortices (AP: 7.0 mm; ML:
3.0 mm from bregma). Starting 1 week after surgery, dig-
ital video–electroencephalography (EEG) recordings were
carried out: a 15 h session (from 18:00 to 09:00 h) and a 7 h
session (from 10:00 to 17:00 h) from 5- to 8-weeks-old. In
total, >132 h of video-EEG recordings were analyzed at
each week of age from six rats.
High-performance liquid chromatography (HPLC)
analysis
Levels of DA and its metabolites were measured using a
previously reported method.17 Briefly, male WT and Scn1a
mutant rats were sacrificed at 8–weeks of age. Striatum,
NA, midbrain, and frontal cortical regions were dissected,
frozen in liquid nitrogen, and stored until homogenization
with 10 volumes of 200 mM ice-cold perchloric acid with
10 mM ethylene diamine tetraacetic acid (EDTA).
Homogenized samples were centrifuged at 11,750 g for
20 min at 4°C, and the supernatant was filtered (0.45 lm)
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chromatography (HPLC) with electrochemical detectors
(HPLC-ECD; Tosoh, Co., Tokyo, Japan). Regional concen-
trations of DA and the metabolites 3,4-dihydroxyphenylace-
tic acid (DOPAC) and homovanillic acid (HVA) were
measured. The HPLC system consisted of a delivery pump
(PX-8020; Tosoh, Co.) and an analytical column (EICOM-
PAK SC-5ODS, 3.0 mm 9 150 mm; Eicom, Co., Kyoto,
Japan). An electrochemical detector (EC-8020; Tosoh, Co.)
with glassy carbon was used with a voltage setting of
700 mV and an Ag/AgCl reference electrode. A mobile
phase containing 0.1 M citrate-sodium acetate buffer (pH
3.5), methanol (17% vol/vol), EDTA-2Na, and sodium 1-
octanesulfonate was infused at a flow rate of 0.6 ml/min.
Protein concentration was determined with a protein assay
kit (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
Histologic assessment
At 8–9 weeks of age, male WT and Scn1a mutant rats
were deeply anesthetized with an intravenous injection of
sodium pentobarbital and perfused transcardially with 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4).
Brains fixed in 4% paraformaldehyde were embedded in
paraffin wax. For histologic assessment, paraffin sections
(4 lm thick) were deparaffinized and rehydrated. To visu-
alize brain structure, sections were stained using the
Kluver-Barrera method using Luxol fast blue and cresyl
violet.
Immunohistochemistry was performed to examine the
number of the dopaminergic neurons in the ventral tegmen-
tal area (VTA) and substantia nigra (SN). An anti-tyrosine
hydroxylase (TH) antibody was used to immunolabel dopa-
minergic neurons. Coronal sections including the VTA and
SN (4 lm thick) were autoclaved at 120°C for 5 min for
antigen retrieval. Endogenous peroxidases were quenched
by incubation with 0.3% hydrogen peroxide in methanol.
After incubating the slides with blocking serum for 1 h at
room temperature, sections were incubated with the mouse
anti-TH antibody (1:1,000; Millipore, Billerica, MA,
U.S.A.) in a humidified chamber overnight at 4°C. The
sections were then incubated with a biotinylated mouse
polyclonal secondary antibody (Vector Laboratories,
Burlingame, CA, U.S.A.). To reveal the staining, we used an
avidin-biotinylated peroxidase complex (ABC) kit (Vecta-
stain Elite ABC kit; Vector Laboratories) and diaminobenzi-
dine (DAB) substrate kit (Vector Laboratories). Using a
microscope (BH-2; Olympus, Tokyo, Japan), the number of
the TH-positive cells in the VTA and SN pars compacta
were counted in coronal sections (n = 3 rats, each group).
To assess the expression of Nav1.1 on dopaminergic
neurons in the VTA and SN in WT littermate controls and
Scn1a mutant rats, we performed fluorescent immunohis-
tochemistry. Sagittal and coronal sections including the
VTA and SN were dissected and postfixed with 4% para-
formaldehyde in 0.1 M phosphate-buffered saline (PBS)
(pH 7.4) at 4°C. Brains were cryoprotected in PBS
containing 30% sucrose prior to cryostat sectioning. Sec-
tions (10–20 lm thick) were incubated overnight at 4°C
with primary antibodies diluted in PBS. Dopaminergic
neurons and Nav1.1 were stained with mouse anti-TH anti-
body (1:1,000; Millipore) and goat anti-Nav1.1 antibody
(1:200; Santa Cruz Biotechnology, Santa Cruz, CA,
U.S.A.), respectively. Next, sections were incubated with
secondary antibodies for 2 h at room temperature. The sec-
ondary antibodies were rhodamine-labeled anti-mouse
antibody (1:100; Sigma Aldrich, St. Louis, MO, U.S.A.)
and fluorescein isothiocyanate (FITC) –labeled anti-goat
antibody (1:100; Santa Cruz Biotechnology). Images were
obtained with a fluorescence microscope (BIOREVO, BZ-
8100; Keyence, Osaka, Japan). Negative controls that were
not incubated with primary antibodies showed no staining.
Treatment withMPH for neurologic symptoms and HIS
MPH is currently the most common treatment for
ADHD. MPH blocks DA transporters and robustly
increases DA release in the NA and dorsal striatum in
rats.18 We wished to examine the effects of MPH on
neurologic symptoms. One hour after intraperitoneal
administration of saline or 0.5 mg/kg MPH (Sigma
Aldrich), behavioral tests were conducted on WT and
Scn1a-mutant rats. Behavioral studies included grooming,
open field test, locomotor activity, rotarod test, and Barnes
maze.
Because some psychotropic agents aggravate epileptic
seizures, we examined the effect of MPH on HIS. One hour
after intraperitoneal administration of saline, 0.5 or 2.0 mg/
kg of MPH, HIS were evoked by hot water baths at 45°C as
described previously.16 Briefly, rats at 5 weeks of age were
placed in a water bath at 45°C for a maximum of 5 min or
until a seizure onset. In this experimental condition, HIS
were never evoked in WT controls. The duration of HIS,
latency until onset of HIS, and rectal temperature at the end
of the hot water bath were assessed. The duration of HIS
was measured using video-EEG monitoring as described
earlier.
Statistical analyses
Data are presented as average  standard error of the
mean (SEM) and reported as significant at p < 0.05. The
data analyses were performed using nonrepeated measures
analysis of variance (ANOVA) with Dunnett’s post hoc test.
The data were compared using the paired t-test for cases
involving two groups as appropriate.
Results
General health and neurologic screen
Table S1 lists general health conditions and neurologic
reflexes of WT and Scn1a- mutant rats at 5 weeks of age.
Both genotypes did not differ significantly in terms of
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Behavioral studies
Repetitive self-grooming behavior
The results for repetitive self-grooming are shown in
Figure 1A. During the 10-min test, while WT littermate
controls spent 47  10 s grooming, Scn1a mutant rats
groomed for significantly longer (89  15 s) (p =
0.029).
Open field and locomotor activity
Scn1a-mutant rats traveled significantly farther than WT
littermate controls (Fig. 1C,D), but spent less time in the
center area of the open field during 10 min test sessions
(Fig. 1E). Scn1a-mutant rats displayed hyperactivity and
anxiety-like behavior.
Elevated plus-maze test
Figure 1F illustrates anxiety-like behavior assessed by
the elevated plus-maze task. Percentage of time spent in the
open arms did not differ significantly between WT litter-
mate controls (25.2  3.1%) and Scn1a-mutant rats
(30.4  2.9%) (p = 0.160).
Three-chamber social interaction test
Both WT littermate controls and Scn1a-mutant rats dem-
onstrated a significant preference for spending time in the
chamber containing a stranger versus spending time explor-
ing the chamber containing an empty cage (Fig. 1G; WT,
stranger vs. empty, 378.8  22.5 s vs. 110.4  15.9 s,
p < 0.001; Scn1a mutant, 402.7  17.9 s vs. 108.6 
A B C D E
F G H
Figure 1.
Scn1a-mutant rats exhibit increased self-grooming, hyperactivity, and anxiety-like behaviors. (A) Scn1a-mutant rats spent significantly
longer time grooming than WT rats. (B) Scn1a-mutant rats at 5 weeks of age appeared physically normal; however, one of 17 Scn1a-
mutant rats showed scattered fur on the head at 3 months of age potentially due to over-grooming. (C) Representative traces in a novel
open field to assess exploratory locomotion. (D) Scn1a-mutant rats traversed more total distance in the novel open field as compared to
WT. (E) Scn1a-mutant rats spent less time in the center area of the open field thanWT. (F) No genotypic difference in anxiety-like behav-
iors on the elevated plus-maze. (G) Amount of time spent in the chamber containing the stranger rat in a wire cage versus amount of time
spent in the chamber containing an identical but empty wire cage. (H) Amount of time spent in the chamber containing the stranger or
familiar rat. Both genotypes demonstrated significant sociability and preference for social novelty. There was no difference within geno-
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12.3 s, p < 0.001). In the test of preference for social nov-
elty, both WT littermate controls and Scn1a-mutant rats
demonstrated a significant novelty preference (Fig. 1H;
WT, stranger vs. familiar: 280.0  13.1 s vs. 216.4 
12.8 s, p < 0.001; Scn1a, 292.4  12.0 s vs. 197.2 
9.5 s, p < 0.001). Together, the results from the three-
chamber social interaction tests show that WT and Scn1a-
mutant rats have similar sociability and novelty
preference.
Barnes maze
Compared to WT littermate controls, Barnes maze
acquisition was significantly slower in Scn1a-mutant rats
(Fig. 2A–C). Acquisition trials revealed that Scn1a-
mutant rats committed more errors than WT controls in
the first entry into the escape box on days 2, 3, and 5
(Fig. 2A). The distance to reach the target hole in
Scn1a-mutant rats was longer than that of WT controls
on days 2–6 (Fig. 2B). Latency to reach the correct
hole above the escape box in Scn1a mutant rats was
longer than that of WT littermate controls on day 5
(Fig. 2C).
Motor function tests
There were no statistical differences between WT
littermate controls and Scn1a-mutant rats at a constant
rotarod speed of 4/60 s1 (Fig. 2D; WT, 153.1 
22.1 s; Scn1a, 106.5  15.9 s, p = 0.100). However,
compared with WT littermate controls, Scn1a-mutant
rats spent significantly less time on the accelerating ro-
tarod (Fig. 2E; WT, 102.3  7.0 s; Scn1a, 73.6 
7.6 s, p = 0.022).
Long-term video-EEGmonitoring
We analyzed >132 h of video-EEG recordings at each
week of age from six Scn1a mutant rats and observed no
spontaneous seizures and no clear epileptiform discharges
(Fig. S1).
HPLC analysis
To assess a potential relationship between brain neuro-
chemistry and behavioral disruptions in Scn1a mutant rats,
we quantified the levels of DA, DOPAC, and HVA in vari-
ous brain regions (Fig. 3). We compared DA, DOPAC, and
HVA levels in the striatum, NA, midbrain, and frontal cor-
tex ofWT littermate control and Scn1a-mutant rats. Overall,
compared to WT controls, we found that Scn1a rats had sig-
nificantly lower DA levels in the striatum (WT, 481.7 
14.9 pmol/mg protein; Scn1a, 366.7  40.0 pmol/mg pro-
tein, p = 0.022) and in the NA (WT, 226.4  21.0 pmol/
mg protein; Scn1a, 169.3  11.0 pmol/mg protein,
p = 0.034). Scn1a rats also had diminished DOPAC levels,
but only in the NA (WT, 55.1  5.1 pmol/mg protein;
Scn1a, 42.0  2.3 pmol/mg protein, p = 0.041).
Histologic assessment
We assessed gross brain structure with Kluver-Barrera’s
staining to visualize myelin sheathes and neuronal cell
bodies. There were no major anatomic abnormalities in the
midbrain (Fig. S2A), hippocampus (Fig. S2B), cerebellum
(Fig. S2C), or the layering of either the frontal cortex (Fig.
S2D) or the cerebellar cortex (Fig. S2E) of Scn1a rats. Of
interest, the number of TH-positive cells in coronal sections
that included the VTA and the SN did not differ between




Scn1a-mutant rats show impaired
spatial learning and memory in the
Barnes maze. (A) Number of errors
to the first entry into the escape box.
(B) Distance to reach the target hole.
(C) Latency to reach the correct hole
above the escape box. (D,E) Rotarod
test revealed that Scn1a-mutant rats
have deficits of motor coordination.
Motor function was assessed by using
Rotarod test at 4/60 s1(D) and
accelerated from 4/60 to
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 7.9 cells/slide; Scn1a, 127.9  11.2 cells/slide, p =
0.85, six slides from three rats per genotype).
Next, we used immunofluorescence to study the distribu-
tion of Nav1.1 subunits on dopaminergic cells (using TH as
a marker) in Scn1a rats. Although Nav1.1 staining was also
found on cells unlabeled for TH, we found many Nav1.1
puncta located on TH-positive dopaminergic neurons from
sagittal sections of the VTA (Fig. 4C–E), as well as coronal
sections of the SN (Fig. 4F–H).
MPH treatment for neurologic symptoms of Scn1a rats
Next, we wished to determine if the commonly used drug
MPH could improve the neurologic deficits exhibited by
Scn1a rats. Compared to vehicle saline treatment alone,
MPH treatment (0.5 mg/kg) shortened the total traveled dis-
tance of Scn1a-mutant rats in the open field (Fig. 5A; sal-
ine, 34.4  3.0 m; MPH, 26.5  2.0 m, p = 0.004). Scn1a
rats treated with MPH also spent more time in the center
area of the open field compared to saline-treated Scn1a rats
(Fig. 5B; saline 24.4  3.8 s; MPH, 36.2  3.7 s,
p = 0.009). These results suggest that MPH reduces anxi-
ety-like behaviors in Scn1a rats.
On acquisition trial day 2 in the Barnes maze (Fig. 5C),
MPH treatment (0.5 mg/kg) of Scn1a rats significantly
reduced the number of errors (Fig. 5D; saline, 6.8  1.1
errors; MPH, 2.6  0.6 errors, p = 0.003) and the latency
time (Fig. 5F; saline, 41.3  7.3 s; MPH, 23.4  3.4 s,
p = 0.039) to reach the target hole. In contrast, WT litter-
mates were unaffected by MPH treatment on both the open
field and Barnes maze tests (Fig. 5A,B,G–I). Nevertheless,
MPH treatment did not change grooming time and motor
balance in both WT and Scn1a-mutant rats (Fig. S3). Taken
together, MPH improved hyperactivity, anxiety-like behav-
iors, and spatial learning in Scn1a-mutant rats.
Effect of MPH onHIS in Scn1a-mutant rats
Figure 6A illustrates representative EEG recordings from
the frontal cortex of HIS in Scn1a-mutant rats treated with
either saline (top) or 0.5 mg/kg of MPH (bottom). Treating
Scn1a rats with either 0.5 or 2 mg/kg of MPH markedly
reduced seizure duration (Fig. 6B; saline, 62.6  12.6 s;
0.5 mg/kg of MPH, 20.5  5.1 s, p = 0.005; 2 mg/kg of
MPH, 14.3  3.5 s, p = 0.001). In addition, treatment with
a higher concentration of MPH (2 mg/kg) increased HIS
threshold in Scn1a rats so that HIS were triggered by a sig-
nificantly longer immersion in hot water (Fig. 6C; saline,
235.6  13.9 s; 2 mg/kg of MPH, 276.1  7.0 s, p =
0.012) and a significantly higher rectal temperature com-
pared with saline-treated rats (Fig. 6D; saline, 43.3
 0.1°C; 2 mg/kg of MPH, 43.7  0.1°C, p = 0.040).
Figure 3.
Comparison of the levels of DA and
its metabolites in different brain
structures. Levels of DA, DOPAC,
and HVA in the striatum, nucleus
accumbens, midbrain, and frontal
cortex in Scn1a-mutant rats
compared withWT controls. The
level of DA in the striatum and the
levels of DA and DOPAC in the
nucleus accumbens from Scn1a-
mutant rats were significantly lower
than those fromWT controls. Each
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These results strongly suggest that MPH treatment increases
the resistance of Scn1a rats to HIS.
Discussion
Developmental disorder–like behaviors in Scn1a-mutant
rats
Behavioral studies revealed that Scn1a-mutant rats
have increased grooming time (repetitive behavior),
hyperactivity, anxiety-like behaviors, impaired spatial
learning, and motor imbalance. Heterozygous Scn1a-
knockout (KO) mice also display impaired social behav-
iors in addition to those behavioral abnormalities found in
Scn1a-mutant rats.19,20 The absence of impaired social
behaviors in Scn1a-mutant rats may depend on the age
tested (adult vs. young adult), frequency of spontaneous
seizures (some vs. none), or functional properties of
mutant Nav1.1-containing channels (null vs. partial func-
tion lowering). Hippocampal GABAergic interneurons
from Scn1a-mutant rats are less excitable compared with
those from WT controls.15
Comorbidity of epilepsy and developmental disorders are
not rare,21 and recurrent seizures are associated with later
cognitive impairment in rats.22,23 Heterozygous Scn1a-KO
mice with developmental disorder–like behaviors have
spontaneous seizures. In this mouse model, it is difficult to
evaluate the impact of recurrent seizures on psychomotor
development. With long-term EEG recordings, we did not
detect spontaneous seizures in Scn1a-mutant rats. This find-
ing suggests that Scn1a mutation itself can cause neurode-
velopmental disorder–like behaviors that include repetitive
behavior, hyperactivity, anxiety-like behavior, impaired
spatial learning, and motor imbalance.
Pathophysiologic basis of developmental disorder–like
behaviors
Dravet syndrome patients with SCN1A mutations show





Nav1.1-containing channels are expressed on dopaminergic neurons in the VTA and SN of Scn1a-mutant rats. Immunohistochemistry of
TH-positive cells in a sagittal section (A) and a coronal section (B) including the VTA and SN. Boxed areas (white squares) indicate the
observed region of the immunofluorescence. All dopaminergic neurons (red, C,F) in the VTA and SN were Nav1.1-positive (green, D,
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hyperactive as well. Brain imaging studies of patients with
ADHD have shown disrupted neurotransmission of the mes-
olimbic DA reward pathway (projection from the VTA to
the NA).24,25 Midbrain dopaminergic neurons play a key
role in cognition, motivation, reward, and regulation of
coordinated movements.26,27 Therefore, using HPLC, we
measured DA and its metabolites in several brain areas of
Scn1a-mutant rats and discovered decreased DA levels in
the NA and the striatum. Lower DA levels in the mesolim-
bic reward pathway may underlie hyperactivity and the cog-
nitive impairment associated with Scn1amutation.
Why are DA levels in the mesolimbic reward pathway in
Scn1a-mutant rats significantly lower than in WT littermate
controls? Counting the number of TH-positive dopaminer-
gic neurons in the VTA and SN revealed no difference in
the amount of dopaminergic neurons between WT litter-
mate controls and Scn1a-mutant rats. Although the number
of cells may be comparable, DA content in the dopaminer-
gic neuron–projecting area in Scn1a-mutant rats may be
lower than that of WT littermate controls. Immunofluores-
cence revealed that Nav1.1 localized to TH-positive
dopaminergic neurons. Dopaminergic neurons in the VTA
fire spontaneously in a pacemaker-like manner, and pace-
making is inhibited by blocking voltage-dependent sodium
current using tetrodotoxin.28 Therefore, in the VTA of
Scn1a-mutant rats, the electrophysiologic properties of the
A B
C D E F
G H I
Figure 5.
MPH treatment improved hyperactivity, anxiety-like behavior, and spatial memory in Scn1a-mutant rats. Intraperitoneal administration of
MPH significantly shortened the total traveled distance (A) and increased time spent in the center area (B) of the open field in Scn1a-
mutant rats. (C) Representative traces of acquisition trial day 2 in the Barnes maze when Scn1a-mutant rats are treated with saline (top)
and MPH (bottom). (D) The number of errors made by Scn1a-mutant rats was markedly decreased on day 2 when treated with MPH as
compared with saline. (E) Distance and (F) time of latency to reach the target hole were also assessed in rats treated with saline and
MPH. In contrast, there were no differences between treatments with MPH and saline inWT controls in the open field (A,B) and Barnes
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sodium current may be altered by the N1417H-Scn1amuta-
tion and in turn modify the firing properties of these dopa-
minergic neurons.
Effects of MPH on developmental disorder–like
behaviors and HIS
MPH is the most common treatment for patients with
ADHD. MPH increases brain DA and norepinephrine levels
by blocking presynaptic reuptake transporters. Because
Scn1a-mutant rats exhibit hyperactivity and low levels of
DA in the NA, we attempted to rescue DA levels with intra-
peritoneal administration of MPH. We found that at a dose
normally administered to patients with ADHD, MPH
improved hyperactivity and spatial learning in Scn1a-
mutant rats. Treatment with clonazepam, an enhancer of
GABA-mediated neurotransmission, improved autistic-like
behaviors in Scn1a-KO mice.19 We propose that MPH can
be another candidate to treat developmental disorders asso-
ciated with SCN1Amutation.
How MPH affects epileptic seizures is unclear. Some
studies revealed that MPH treatment had no adverse effect
on epileptic seizures,29,30 or might worsen epileptic seizures
in ADHD patients with epilepsy.31 Given that patients with
SCN1A mutations often show intractable epilepsy, we
wanted to determine if MPH can control Scn1a mutation–
related seizures. Surprisingly, MPH treatment strongly sup-
pressed HIS in Scn1a-mutant rats. It is notable that MPH
reduced HIS to an extent similar to the most effective anti-
convulsant drugs such as diazepam and potassium bromide
in our previous study.16
Dysfunction of GABAergic neurons is considered as
the pathophysiologic basis of epilepsy caused by Scn1a
mutations.1,2,15 Indeed, anticonvulsants such as valproic
acid, benzodiazepines, and potassium bromide—drugs
that enhance GABA-mediated inhibition—were effective
in Dravet syndrome patients with SCN1A mutations.
Although we did not determine how MPH elevates sei-
zure threshold, MPH may directly suppress brain excit-
ability, enhance GABA-mediated inhibition, or have
another unknown target. Further studies to elucidate the
anticonvulsant action(s) of MPH in this model may lead
to new treatments for epileptic patients with SCN1A
mutations.
In conclusion, we demonstrated that Scn1a mutation can
cause developmental disorder–like behaviors without recur-
ring epileptic seizures. Low DA levels in the NA and the
striatum may underlie these developmental disorder–like
behaviors. MPH treatment improved hyperactivity and
learning impairments in Scn1a-mutant rats. Unexpectedly,




MPH treatment shortened the duration of HIS and increased seizure threshold with dose dependence in Scn1a-mutant rats. (A) Repre-
sentative EEG recordings from the frontal cortex during HIS in Scn1a rats pretreated with saline (top) or 0.5 mg/kg of MPH (bottom). (B)
The mean duration of HIS in Scn1a rats pretreated with saline, 0.5 mg/kg of MPH, and 2 mg/kg of MPH. (C) Latency to HIS onset. (D) Rec-
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might be effective to treat neurodevelopmental disorders
and epilepsy in patients with Dravet syndrome and GEFS+.
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Figure S1. Long-term video-EEGmonitoring.
Figure S2. Scn1a-mutant rats exhibit no histologic
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Figure S3.MPH treatment did not change grooming time
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